Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a Munich-based company specializing in biosensor development, on October 2, 2024. This acquisition strengthens Bruker’s biophysical portfolio for analyzing molecular interactions and kinetics.
Dynamic Biosensors develops technologies for studying complex molecular interactions, including the heliX cyto instrument for single-cell Interaction Cytometry and the heliX+ instrument utilizing switch SENSE technology. These additions complement Bruker’s existing high-throughput Surface Plasmon Resonance (SPR) portfolio.
The combined Bruker Biosensors business now offers an innovative range of instruments and workflows for drug discovery and basic research. Bruker Biosensors expects additional revenues greater than $5 million from the Dynamic Biosensors acquisition in fiscal year 2025, with no material impact on EPS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.